EIGR Insider Trading Activity and SEC Form 4 Filings
EIGR insider trading summary
No open-market insider purchases or sales of Eiger BioPharmaceuticals, Inc. (EIGR) have been reported on SEC Form 4 in the past 12 months.
Latest EIGR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2023 | Richard A Kayne | Insider | Buy | $7K (23,398 @ $0.30) |
| Nov 1, 2023 | Richard A Kayne | Insider | Buy | $28K (100,000 @ $0.28) |
| Oct 31, 2023 | Richard A Kayne | Insider | Buy | $3K (11,987 @ $0.26) |
| Oct 31, 2023 | Leen Kawas | Insider | Buy | $3K (11,987 @ $0.26) |
| Oct 31, 2023 | Leen Kawas | Insider | Buy | $3K (12,345 @ $0.26) |
| Oct 31, 2023 | Richard A Kayne | Insider | Buy | $32K (130,509 @ $0.24) |
| Oct 31, 2023 | Richard A Kayne | Insider | Buy | $3K (12,345 @ $0.26) |
| Mar 17, 2023 | Eldon C. Mayer III | Ex VP & Chief Commerc. Officer | Sell | $2K (1,875 @ $1.07) |
| Mar 17, 2023 | Eldon C. Mayer III | Ex VP & Chief Commerc. Officer | Sell | $3K (2,520 @ $1.07) |
| Jan 23, 2023 | Thomas John Dietz | Director | Buy | $72K (50,000 @ $1.43) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.